Q-omics provides the consensus-scored SPANXA2-OT1 profile across patient tissues and cancer cell-line models. SPANXA2-OT1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SPANXA2-OT1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SPANXA2-OT1 RNA expression shows 13,398 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where SPANXA2-OT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXA2-OT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXA2-OT1 survival associations across molecular data types. SPANXA2-OT1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXA2-OT1 RNA expression–survival associations across cancer types. High SPANXA2-OT1 expression shows unfavorable associations in UCEC, READ, HNSC, UVM and LIHC, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SPANXA2-OT1 RNA expression.
This table summarizes SPANXA2-OT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXA2-OT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXA2-OT1 shows lower tumor expression in KIRC, BLCA and UCEC and higher tumor expression in THCA, BRCA and LUAD. The THCA box plot shows higher SPANXA2-OT1 RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p < 0.001).
This table shows molecular features associated with SPANXA2-OT1 in patient tissues and cancer cell lines. In patient samples, SPANXA2-OT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
